bond8k_aug282009.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 28, 2009
BOND LABORATORIES, INC.
| |
|
|
|
Nevada |
333-137170 |
20-3464383 |
|
(State or Other Jurisdiction of
Incorporation or Organization) |
(Commission File Number ) |
(I.R.S. Employer
Identification No.) |
| |
|
|
11011 Q Street, Suite 106A, Omaha, NE |
68137 |
|
(Address of principal executive offices) |
(Zip Code) |
Registrant’s telephone number, including area code: 402-333-5260
(Name, address, including zip code, and telephone number, including area code, of agent for service of process)
NOT APPLICABLE
(Former Name or Former Address, if Changes Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
As used in this report, the terms "we", "us", "our", "our company," or "the Corporation" refers to Bond Laboratories, Inc., a Nevada corporation.
ITEM 3.02 – Unregistered Sale Of Equity Securities.
On August 7, 2009, we began a private financing transaction (the “Financing”) with certain private investors (the “Purchasers”), pursuant to a subscription agreement (the “Agreement”). The transaction was completed on August 28, 2009 for an aggregate purchase price of Four Hundred and Fifty-Six Thousand,
Two Hundred and Fifty Dollars ($456,250). In connection with the Financing, we issued to the Purchasers, in reliance upon the exemption provided by Sections 4(2) and 4(6) under the Securities Act of 1933, as amended, for a transaction not involving a public offering and pursuant to Rule 506 of Regulation D promulgated thereunder, 2,281,250 common shares of our Company and Series A warrants to purchase 2,281,250 shares of our common stock. The Series A Warrants have a three year term, an exercise price equal to
thirty-five cents ($0.35) per share and contain no anti-dilution or pre-emptive rights.
Subsequent to the completion of the Financing, we closed a follow-on offering, in reliance upon the exemption provided by Sections 4(2) and 4(6) under the Securities Act of 1933, as amended, for a transaction not involving a public offering and pursuant to Rule 506 of Regulation D promulgated thereunder, with gross proceeds to the Company
of $68,250 through the issuance of 136,500 common shares of our Company and Series B warrants to purchase 136,500 shares of our common stock. The Series B Warrants have a three year term, an exercise price equal to seventy-five cents ($0.75) per share and contain no anti-dilution or pre-emptive rights.
Item 9.01. Financial Statements, Pro Forma Financial Information and Exhibits.
(d) Exhibits
None.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
September 15, 2009
Bond Laboratories, Inc.
| |
By: |
/s/ John S. Wilson |
| |
John S. Wilson |
| |
Chief Executive Officer, Director |